IDEXX Laboratories Inc

IDEXX Laboratories Inc(IDXX)股票分析

$560.380

-6.332 (-1.13%)收盘时

Loading chart…
最高
569.555
开盘
564.800
成交量加权均价
562.74
成交量
398.28K
市值
40.79B
最低
558.290
成交额
224.13M
企业价值/息税折旧摊销前利润(TTM)
22.78

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants.

AI 分析 of IDEXX Laboratories Inc (IDXX)

买入

IDEXX Laboratories Inc is a good buy right now at the current price of $560.36, especially considering its strong recent performance with a 5-day change of +8.18% and a gross margin of 64.04% in Q2 2026. The stock has shown resilience with a high RSI of 81.798, indicating strong momentum. However, the main risk is the recent insider selling by Director Lawrence D. Kingsley, who sold 2,203 shares at $532.08, which may raise concerns about insider confidence.

分析师评级(10)

上行空间 +41.47%
买入
6 买入
3 持有
1 卖出
当前: 560.38
最低
750.00
平均
792.78
最高
850.00

KeyBanc

2026-10-12

目标价

—

Sector Weight

Barclays

2026-08-11

目标价

$710

增持

Citi

2026-08-05

目标价

$670

中性

UBS

2026-07-27

目标价

$620

中性

Stifel

2026-07-15

目标价

$564.42

买入

估值指标

IDEXX Laboratories Inc(IDXX)当前预期市盈率为 31.45,5 年平均预期市盈率为 45.80。

预期市盈率

低估
5 年均值 P/E
45.80
当前P/E
31.45
高估
54.95
低估
36.65

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
31.91
当前EV/EBITDA
22.78
高估
37.94
低估
25.88

预期市销率

低估
5 年均值 P/S
10.28
当前P/S
8.47
高估
12.07
低估
8.49

Alphio AI 对 IDXX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%IDXX

$650.45

情景价格

基

基准

基准 · 50%IDXX

$608.98

情景价格

悲

悲观

悲观 · 25%IDXX

$597.63

情景价格

持有 IDXX 的大户

B

Baron Capital Group, Inc.

+ 持有IDXX

+12.16%

3个月收益率

E

Entropy Technologies, LP

+ 持有IDXX

+8.72%

3个月收益率

J

Joel R. Mogy Investment Counsel Inc.

+ 持有IDXX

+7.75%

3个月收益率

V

Vulcan Value Partners, LLC

+ 持有IDXX

+7.58%

3个月收益率

T

Trexquant Investment LP

+ 持有IDXX

+7.53%

3个月收益率

S

Squarepoint OPS LLC

+ 持有IDXX

+6.43%

3个月收益率

事件时间线

2026-09-16 (ET)

07:30:00

IDEXX Laboratories Acquires CoVetAI to Expand Software Ecosystem

2026-08-11 (ET)

07:30:00

IDEXX Launches Catalyst proBNP Test, Enhancing Cardiac Testing Capabilities

2026-08-04 (ET)

09:00:00

IDEXX Laboratories Q2 Revenue $1.22B Beats Expectations

08:30:00

Idexx Reports Q2 EPS of $4.27, Beating Consensus of $3.93

07:00:00

2026 EPS Consensus at $14.66, Revenue View Adjusted to $4.70B-$4.745B

资讯

IDXX 常见问题 —— 由 Alphio AI 解答

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

IDEXX Laboratories Inc is a good buy right now at the current price of $560.36, especially considering its strong recent performance with a 5-day change of +8.18% and a gross margin of 64.04% in Q2 2026. The stock has shown resilience with a high RSI of 81.798, indicating strong momentum. However, the main risk is the recent insider selling by Director Lawrence D. Kingsley, who sold 2,203 shares at $532.08, which may raise concerns about insider confidence.

10 analysts cover IDXX: 6 rate it Buy, 3 Hold and 1 Sell. The average price target is 792.78.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易